Mucinex

Manufacturer
Reckitt Benckiser LLC
Effective date
2026-05-12
Label type
HUMAN OTC DRUG LABEL
Version
2
Source
weekly-update
Hydrated at
2026-07-17 21:41:49

Label at a glance#

ProductMucinex DS 12HR COLD, FEVER and SINUS
Active ingredientNAPROXEN SODIUM, PSEUDOEPHEDRINE HYDROCHLORIDE
Label structure12 sections

Label contents#

Full prescribing information#

OTC - ACTIVE INGREDIENT SECTION

Active ingredients
(in each extended-release tablet)


Naproxen sodium 220 mg
(naproxen 200 mg) (NSAID)


Pseudoephedrine HCl 120 mg,

OTC - PURPOSE SECTION

Purposes
(in each extended-release tablet)

Naproxen sodium 220 mg
(naproxen 200 mg) (NSAID)*........Pain reliever/fever reducer


Pseudoephedrine HCl 120 mg,
extended-release..................................Nasal decongestant
*nonsteroidal anti-inflammatory drug

INDICATIONS & USAGE SECTION

Uses
temporarily relieves these cold, sinus, and flu symptoms:
■ sinus pressure

■ minor body aches and pains
■ headache
■ nasal and sinus congestion (promotes sinus drainage
and restores freer breathing through the nose)
■ fever

WARNINGS SECTION

Warnings
Allergy alert:
Naproxen sodium may cause a severe
allergic reaction, especially in people allergic to aspirin.


Symptoms may include:
■ hives ■ facial swelling ■ asthma (wheezing)
■ shock ■ skin reddening ■ rash ■ blisters


If an allergic reaction occurs, stop use and seek medical
help right away.


Stomach bleeding warning: This product contains an
NSAID, which may cause severe stomach bleeding.
The chance is higher if you:
■ are age 60 or older
■ have had stomach ulcers or bleeding problems
■ take a blood thinning (anticoagulant) or steroid drug
■ take other drugs containing prescription or nonprescription
NSAIDs (aspirin, ibuprofen, naproxen, or others)
■ have 3 or more alcoholic drinks every day while using
this product

■ take more or for a longer time than directed


Heart attack and stroke warning: NSAIDs, except
aspirin, increase the risk of heart attack, heart failure, and
stroke. These can be fatal. The risk is higher if you use
more than directed or for longer than directed.

OTC - DO NOT USE SECTION

Do not use
■ if you have ever had an allergic reaction to any other
pain reliever/fever reducer
■ right before or after heart surgery
■ if you are now taking a prescription monoamine oxidase
inhibitor (MAOI) (certain drugs for depression, psychiatric,
or emotional conditions, or Parkinson’s disease), or for
2 weeks after stopping the MAOI drug. If you do not
know if your prescription drug contains an MAOI, ask a
doctor or pharmacist before taking this product.
■ in children under 12 years of age

OTC - ASK DOCTOR/PHARMACIST SECTION

Ask a doctor before use if
■ the stomach bleeding warning applies to you
■ you have a history of stomach problems, such as
heartburn
■ you have high blood pressure, heart disease, liver
cirrhosis, kidney disease, asthma, thyroid disease,
diabetes, have trouble urinating due to an enlarged
prostate gland, or had a stroke
■ you are taking a diuretic
■ you have problems or serious side effects from taking
pain relievers or fever reducers

Ask a doctor or pharmacist before use if you are
■ under a doctor’s care for any serious condition
■ taking aspirin for heart attack or stroke, because
naproxen may decrease this benefit of aspirin
■ taking any other drug

When using this product
■ take with food or milk if stomach upset occurs

Stop use and ask a doctor if
■ you experience any of the following signs of stomach
bleeding:
■ feel faint ■ vomit blood
■ have bloody or black stools
■ have stomach pain that does not get better


■ you have symptoms of heart problems or stroke:
■ chest pain ■ trouble breathing
■ weakness in one part or side of body
■ slurred speech ■ leg swelling


■ redness or swelling is present in the painful area
■ any new symptoms appear
■ fever gets worse or lasts more than 3 days
■ you have difficulty swallowing or the extended-release
tablet feels stuck in your throat
■ you get nervous, dizzy, or sleepless
■ nasal congestion lasts more than 7 days

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

If pregnant or breast-feeding, ask a health professional
before use. It is especially important not to use naproxen
sodium at 20 weeks or later in pregnancy unless definitely
directed to do so by a doctor because it may cause problems
in the unborn child or complications during delivery.


Keep out of reach of children. In case of overdose, get
medical help or contact a Poison Control Center right away.

DOSAGE & ADMINISTRATION SECTION

Directions
■ do not take more than directed
■ the smallest effective dose should be used

■ swallow whole; do not crush or chew
■ drink a full glass of water with each dose
■ adults and children 12 years and older:
1 extended-release tablet every 12 hours; do not
take more than 2 extended-release tablets in 24 hours
■ children under 12 years: do not use

OTHER SAFETY INFORMATION

Other information
■ each extended-release tablet contains
: sodium 21 mg
■ FDA approved dissolution specification differs from the
USP dissolution specification
■ store at 20-25°C (68-77°F)
■ store in a dry place

INACTIVE INGREDIENT SECTION

Inactive ingredients
colloidal silicon dioxide, hypromellose, lactose
monohydrate, magnesium stearate, microcrystalline
cellulose, polyethylene glycol, polysorbate 80, povidone,
talc, titanium dioxide

OTC - QUESTIONS SECTION

Questions? 1-866-MUCINEX (1-866-682-4639)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

full carton labelfull carton label

back labelback labellabel 2label 2

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
QR code linkQR Codewww.mucinex.com/pages/product-faqs72854-223 back label 2.jpg

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 16 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
72854-22372854-223-20

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDENAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-1784e616aacf4f…
2026-08-18 06:07:402026-07A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-1731067a03dcf5…
2025-08-23 18:47 UTC2025-08A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-176a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-1703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-172680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-175bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-1779d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-171e350fbaab3a…
2024-05-31 18:47 UTC2024-05A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-178072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-175c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-175d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-174b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-1774a2ff9319b5…
2022-03-09 01:35 UTC2022-03A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-17782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-1787673890dc5c…
2021-03-12 10:30 UTC2021-03A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-175aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-178869cabd3fbd…
2020-11-12 02:37 UTC2020-11A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-17c0c555d07b60…
2019-12-14 00:12 UTC2019-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-173f01610625f2…
2019-09-15 20:21 UTC2019-09A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDEEQ 200MG BASE;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-17b00525d2431f…
2019-07-19 19:46 UTC2019-07A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDEEQ 200MG BASE;120MGTABLET, EXTENDED RELEASE / ORAL2004-03-17ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-176a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-171c564ffb4f44…
2023-12-20 04:57 UTC2023-12A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-179b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-173f0d92c62455…
2023-05-13 08:27 UTC2023-05A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17053a50430f4f…
2023-01-26 05:58 UTC2023-01A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-173bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-173a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A076518-001NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE220MG;120MGTABLET, EXTENDED RELEASE / ORALRS2004-03-17f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Mucinex DS 12HR COLD, FEVER and SINUSNAPROXEN SODIUM, PSEUDOEPHEDRINE HYDROCHLORIDEReckitt Benckiser LLC4e7e6674-c1ce-ea61-e063-6294a90afe042026-05-12WarningsExact identifier
ndc (package): 72854-223-20
ndc (product): 72854-223
ndc11 (package): 72854022320
spl id: 51a2ac68-9003-93ef-e063-6294a90abd6b
spl set id: 4e7e6674-c1ce-ea61-e063-6294a90afe04

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.